1 Answers
Olanib Capsule contains Olaparib
Olanib Capsule uses for
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials
Recommended dose is 400 mg taken orally twice daily with or without food. Continue treatment until disease progression or unacceptable toxicity. For adverse reactions, consider dose interruption of treatment or dose reduction.
For moderate renal impairment (CrCl 310 mL/min), reduce dose to 300 mg twice daily
Read more here Olanib